RA Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

RA Capital Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,930,322	Closed	-$28.5M	–	94
2022 Q1	$28.5M	Hold	1,930,322	–	–	0.62%	47
2021 Q4	$25.5M	Hold	1,930,322	–	–	0.45%	54
2021 Q3	$33.7M	Hold	1,930,322	–	–	0.47%	49
2021 Q2	$46.3M	Buy	1,930,322 +1,580,322	+452%	+$41.3M	0.74%	44
2021 Q1	$8.99M	Buy	+350,000	New	+$9.2M	0.14%	74
2019 Q2	–	Sell	-1,441,070	Closed	-$41.2M	–	29
2019 Q1	$41.2M	Hold	1,441,070	–	–	1.78%	16
2018 Q4	$28.5M	Hold	1,441,070	–	–	1.66%	17
2018 Q3	$31.9M	Hold	1,441,070	–	–	1.7%	18
2018 Q2	$11.7M	Hold	1,441,070	–	–	0.76%	22
2018 Q1	$13.7M	Hold	1,441,070	–	–	1.05%	19
2017 Q4	$14.1M	Buy	1,441,070 +850,000	+144%	+$8.85M	1.18%	18
2017 Q3	$4.35M	Hold	591,070	–	–	0.39%	25
2017 Q2	$4.35M	Hold	591,070	–	–	0.5%	21
2017 Q1	$4.62M	Hold	591,070	–	–	0.57%	22
2016 Q4	$4.18M	Buy	+591,070	New	+$4.36M	0.59%	21

Other funds holding KALV

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RA Capital Management's KALV Position: Q2 2022 in Review

RA Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2022, closing a stake of 1,930,322 shares — an estimated $28.5M sold.

RA Capital Management first reported a position in KALV in Q4 2016 and held it in 15 quarters. The position peaked at $46.3M in Q2 2021. 91 funds tracked by Wall St. Rank hold KALV as of Q2 2022.

RA Capital Management reported no remaining KalVista Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
RA Capital Management sold 1,930,322 KalVista Pharmaceuticals shares in Q2 2022, an estimated $28.5M.
RA Capital Management first reported a position in KalVista Pharmaceuticals in Q4 2016 and held it in 15 quarters.
RA Capital Management's KalVista Pharmaceuticals position peaked at $46.3M in Q2 2021.
91 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2022.

Based on RA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.